09 Sep 2015 --- The European Medicines Agency (EMA) has recommended the granting of a marketing authorisation for Praluent (alirocumab) to lower high levels of cholesterol in the blood of people who are unable to control their cholesterol despite taking optimal doses of statins or those who cannot take statins. The medicine should be used in addition to a healthy diet. Other lipid-lowering therapies (statins and others) should also be used if tolerated. High levels of cholesterol in the blood are common risk factors for heart disease, which is the leading cause of death globally.
